來吧，腹部脂肪沒別的招，就是運(yùn)動(dòng)

Scientists know that the type of fat you can measure with a tape isn't the most dangerous.But what is the most effective way to fight internal,visceral fat that you cannot see or feel?The answer:exercise.

科學(xué)家們知道外在的由尺子測量出來的肥胖并不是最可怕的，那對(duì)抗腹部肥胖(就是那些感覺不到看不到的內(nèi)臟脂肪)最有效的方式到底是什么呢?答案就是：運(yùn)動(dòng)。

Researchers at UT Southwestern Medical Center analyzed two types of interventions--lifestyle modification(exercise)and pharmacological(medicine)--to learn how best to defeat fat lying deep in the belly.The study is published in Mayo Clinic Proceedings.

西南醫(yī)學(xué)中心的研究人員分析了兩種類型的干預(yù)措施——生活方式的改變和藥物使用——來了解如何更好的減少腹部脂肪的堆積。這項(xiàng)研究的結(jié)果發(fā)表在Mayo Clinic Proceedings上面。

"Visceral fat can affect local organs or the entire body system.Systemically it can affect your heart and liver,as well as abdominal organs,"said senior author and cardiologist Dr.Ian J.Neeland,Assistant Professor of Internal Medicine."When studies use weight or body mass index as a metric,we don't know if the interventions are reducing fat everywhere in the body,or just near the surface."

“內(nèi)臟脂肪會(huì)影響局部器官或整個(gè)身體系統(tǒng)。系統(tǒng)地說，它可以影響你的心臟和肝臟，以及腹部器官。尼蘭德，內(nèi)科助理教授。“當(dāng)研究使用體重或身體質(zhì)量指數(shù)作為衡量標(biāo)準(zhǔn)時(shí)，我們不知道這些干預(yù)措施是減少了身體各處的脂肪，還是僅僅減少了身體表面的脂肪。”

To find out,the researchers evaluated changes in visceral fat in 3,602 participants over a 6-month period measured by a CT or MRI exam.Both exercise and medicines resulted in less visceral fat,but the reductions were more significant per pound of body weight lost with exercise.

為了找到答案，研究人員對(duì)3602名參與者進(jìn)行了為期6個(gè)月的CT或MRI檢查，評(píng)估了他們內(nèi)臟脂肪的變化。運(yùn)動(dòng)和藥物都能減少內(nèi)臟脂肪，但運(yùn)動(dòng)后每磅體重的減少幅度更大。

"The location and type of fat is important.If you just measure weight or BMI,you can underestimate the benefit to your health of losing weight,"said Dr.Neeland,a Dedman Family Scholar in Clinical Care."Exercise can actually melt visceral fat."

脂肪生成的部位和類型很重要，如果你只是稱體重或者計(jì)算BMI，你可能會(huì)低估減重對(duì)你身體的益處。運(yùn)動(dòng)確實(shí)可以“溶掉”你的腹部脂肪。

Participants in exercise trials were 65 percent female,with a mean age of 54 and mean BMI at enrollment of 31.Exercise regimens were monitored,not self-reported.The majority of exercise trials were performed in the U.S.and Canada,while pharmacologic trials included the U.S.,Canada,Sweden,Japan,and four multinational cohorts.

參與運(yùn)動(dòng)組的志愿者65%是女性，平均年齡54歲，BMI的平均值是31.參與運(yùn)動(dòng)組的志愿者65%是女性，平均年齡54歲，BMI的平均值是31.運(yùn)動(dòng)方案由系統(tǒng)檢測，并非志愿者自我上報(bào)，這樣就減少了偏差。大多數(shù)的運(yùn)動(dòng)干預(yù)試驗(yàn)在美國和加拿大進(jìn)行，而藥物試驗(yàn)部分則安排在美國，加拿大，瑞典，日本和四個(gè)多中心試驗(yàn)組。

The medications used by study participants were FDA approved or in the FDA approval pipeline.

研究參與者使用的藥物是FDA已批準(zhǔn)或者正在申請(qǐng)獲批中的。